Navigation Links
CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
Date:1/31/2008

. Eastern time on Thursday, January 31, 2008 through Saturday, March 1, 2008 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 31898426. An archive of the webcast will be available for 30 days at http://www.curagen.com.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including the histone deacetylase inhibitor, belinostat, and the antibody-drug conjugate, CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Safe Harbor

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to CuraGen's revenue, expenses, losses, income, and future cash and investment positions, including with respect to the fourth quarter and year ended December 31, 2007 and fiscal year 2008, the timing and expected results of our clinical programs, and the development and marketability of planned drugs, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned,"
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
2. CuraGen Appoints Clinical Oncologist as VP of Medical Development
3. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
4. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. CuraGen Corporation Receives Notification from NASDAQ
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...n a provocative new study, a University of Utah sc...s the major cause of global warming cannot be st...ociety builds the equivalent of one new nuclear po...here will be any substantial near-term departure f...de emission rates," says the new paper by Tim Garr...
(Date:11/23/2009)...PRNewswire-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasd...vember27,2009astheex-dividenddateforits$200million...itizationtransactioncompletedonNovember2,2009.Thed...sofrecordontherecorddate,December1,2009.NASDAQhass...pershareofcommonstockforpurposesoftheex-dividendda...
(Date:11/23/2009)...-ImmuneDesignC or p.(IDC)announcedtodaythatDr.Bruc...erhasasuccessfultrackrec or dinbiotechnologyexecut...ratZymoGenetics,inSeattle,WAandChiefScientificOffi...o: http://www.newscom.com/cgi-bin/prnh/20091123/SF...ecutiveOfficercommented,"IamdelightedtowelcomeDr.B...
(Date:11/23/2009)...-FirstCall/--CornerstoneTherapeuticsInc.(Nasdaq: C...iring,developingandcommercializingsignificantprodu...ayannouncedthatCraigA.Collard,PresidentandChiefExe...the21stAnnualPiperJaffrayHealthCareConferenceat3:3...otelinNewYorkCity. ,, Aliveaudioandarchivedwebc...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2
...Management Changes Announced, NEW YORK, March 5 ...nnounced that the company,s Board of Directors,has...chief financial,officer, effective March 31, 2008....recting and managing the company,s fiscal operatio...the organization and its,subsidiaries. Andrew Bonf...
...se II study of 20 patients reported in Annals of O....,(CTI) (Nasdaq: CTIC ; MTA) today announced the ...lts of a limited phase II study of CHOP chemothera...d prednisone) followed by,administration of Zevali...0,years of age or older) with previously untreated...
...lbaum, assistant professor of electrical and compu... received the prestigious Faculty Early Career Dev...n for his pioneering research in the exciting next... This emerging field focuses on harnessing the mag...ctronics ranging from computers to cell phones tha...
Other Biology Technology:Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 2CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 4UD's Appelbaum wins NSF Career Award for research on silicon spintronics 2UD's Appelbaum wins NSF Career Award for research on silicon spintronics 3
(Date:11/24/2009)...rs to understanding how sounds associated with Nav...l or if they hear it at all. , The same type of...ses to detect flaws in the space shuttle,s behemot... peek inside the giant head of a whale. The scans ...of a whale,s hearing anatomy using a breakthrough ...
(Date:11/24/2009)...bby arteries from collapsing have been true life-s...onger needed -- once the arteries are strengthened... no choice but to leave them in place. , Prof. M...t of Biomedical Engineering has developed a new pa...re they,re needed, then dissolves. , "Our new co...
(Date:11/24/2009)... of Medical Toxicology (ACMT) have signed an agree...rnal of Medical Toxicology (JMT), the official jo...s previously published by the University of Pennsy...ogy , an international, peer-reviewed journal, is ... medical toxicology. The quarterly journal focuse...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2A coating for life 2Springer and the American College of Medical Toxicology to work together 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 1Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 8Carondelet St Marys Medical Plaza II Opens In Tucson 55314 1MicroRNA in human saliva may help diagnose oral cancer 9696 1
...ced a major expansion of a lingua franca used to d...s. The expansion provides terms that scientists c...hen a pathogenic or beneficial microbe encounters ...r developing new interventions for preventing infe...g or encouraging the presence of beneficial microb...
...s of other individuals in order to cooperate in co...we humans take for granted. But, according to evol... Institute in Germany, this ability is present in ...April issue of Current Directions in Psychological... gaze and face orientation to monitor others, beha...
...may explain why Graves?disease (GD) attacks the mu... bulge painfully from their sockets, as in the lat...s Stein Eye Institute and Harbor-UCLA Medical Cent...cells of GD patients?immune systems. Reported Mar... deepen understanding of how the autoimmune disord...
Other Biology News:Uniform language for describing genes of pathogenic and beneficial microbes 2Uniform language for describing genes of pathogenic and beneficial microbes 3Man's best friend lends insight into human evolution 2UCLA study uncovers clues for why Graves' disease attacks the eyes 2
Viraffinity 100 from Biotech Support Group
Tumor Suppressor Sampler Kit from BD Biosciences Pharmingen
Mouse Anti-Synapsin I Monoclonal Antibody, Unconjugated, Clone 223 from IMGENEX
Slide Chambers from Novagen
Biology Products: